KR20230129467A - 항-푸코실-gm1 항체를 사용하는 조합 요법 - Google Patents

항-푸코실-gm1 항체를 사용하는 조합 요법 Download PDF

Info

Publication number
KR20230129467A
KR20230129467A KR1020237026366A KR20237026366A KR20230129467A KR 20230129467 A KR20230129467 A KR 20230129467A KR 1020237026366 A KR1020237026366 A KR 1020237026366A KR 20237026366 A KR20237026366 A KR 20237026366A KR 20230129467 A KR20230129467 A KR 20230129467A
Authority
KR
South Korea
Prior art keywords
antibody
seq
sequence
fucosyl
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237026366A
Other languages
English (en)
Korean (ko)
Inventor
위 류
사라 타넨바움-드비르
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20230129467A publication Critical patent/KR20230129467A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237026366A 2021-01-08 2022-01-07 항-푸코실-gm1 항체를 사용하는 조합 요법 Pending KR20230129467A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163135479P 2021-01-08 2021-01-08
US63/135,479 2021-01-08
PCT/US2022/011564 WO2022150557A1 (en) 2021-01-08 2022-01-07 Combination therapy using an anti-fucosyl-gm1 antibody

Publications (1)

Publication Number Publication Date
KR20230129467A true KR20230129467A (ko) 2023-09-08

Family

ID=80119207

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237026366A Pending KR20230129467A (ko) 2021-01-08 2022-01-07 항-푸코실-gm1 항체를 사용하는 조합 요법

Country Status (10)

Country Link
US (1) US20240050564A1 (https=)
EP (1) EP4274850A1 (https=)
JP (1) JP2024503379A (https=)
KR (1) KR20230129467A (https=)
CN (1) CN116745322A (https=)
AU (1) AU2022205648A1 (https=)
CA (1) CA3204392A1 (https=)
IL (1) IL304200A (https=)
MX (1) MX2023007780A (https=)
WO (1) WO2022150557A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201912657D0 (en) * 2019-09-03 2019-10-16 Scancell Ltd Binding members

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US8383118B2 (en) 2005-12-08 2013-02-26 Medarex, Inc. Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
BR122017025062B8 (pt) 2007-06-18 2021-07-27 Merck Sharp & Dohme anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP3255060A1 (en) 2008-12-09 2017-12-13 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
JP6072771B2 (ja) 2011-04-20 2017-02-01 メディミューン，エルエルシー Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子
HK1203971A1 (en) 2012-05-15 2015-11-06 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
US11104739B2 (en) * 2016-04-14 2021-08-31 Bristol-Myers Squibb Company Combination therapy using an anti-fucosyl-GM1 antibody and an anti-CD137 antibody
CN109475634A (zh) * 2016-06-03 2019-03-15 百时美施贵宝公司 用于治疗复发性小细胞肺癌的方法的抗-pd-1抗体
RU2765997C2 (ru) * 2017-03-30 2022-02-07 Мерк Патент Гмбх Комбинация анти-pd-l1 антитела и ингибитора днк-пк для лечения злокачественного новообразования
MY205645A (en) * 2018-06-23 2024-11-02 Genentech Inc Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor

Also Published As

Publication number Publication date
IL304200A (en) 2023-09-01
WO2022150557A1 (en) 2022-07-14
EP4274850A1 (en) 2023-11-15
JP2024503379A (ja) 2024-01-25
CA3204392A1 (en) 2022-07-14
MX2023007780A (es) 2023-07-10
AU2022205648A9 (en) 2024-09-19
US20240050564A1 (en) 2024-02-15
CN116745322A (zh) 2023-09-12
AU2022205648A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
TWI733664B (zh) 包含抗ｐｄ１抗體及另一種抗體之組合的組合物
CN106999594B (zh) 用于治疗瘤形成的治疗组合
RU2733315C2 (ru) Комбинированная терапия для лечения злокачественной опухоли
JP7274426B2 (ja) 抗ｇｉｔｒアゴニスト抗体での癌の処置
US20250361313A1 (en) Combination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody
SG10202111905PA (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
Baldo Monoclonal antibodies approved for cancer therapy
KR20230047498A (ko) 결장직장암을 갖는 환자의 치료에서의 항-pd-1 항체의 용도
KR20170007750A (ko) Ｈｐｖ-음성 암의 치료를 위한 ｐｄｌ-1의 길항제 및 ｐｄ-1의 길항제
US20240279342A1 (en) Compositions and methods for immunotherapy
WO2020007368A1 (zh) 低adcc/cdc功能性单抗及其制备方法与应用
CN111973739B (zh) 抗pd-l1单克隆抗体治疗癌症的用途
US20240050564A1 (en) Combination therapy using an anti-fucosyl-gm1 antibody
KR20230069957A (ko) 암을 갖는 환자의 치료를 위한 pd-1 길항제 및 lag3 길항제 및 렌바티닙 또는 이의 약학적으로 허용가능한 염의 병용 요법
WO2023001118A1 (zh) 抗ox40抗体在联合用药中的应用
AU2007299582B2 (en) Anti-cancer antibodies against Lewisy and Lewisb antigens
EA049752B1 (ru) Комбинированная терапия с применением анти-фукозил-gm1 антитела
WO2025036445A1 (en) Treatment of lung cancer with anti-pd-1 and chemotherapy
WO2020049534A1 (en) Sting agonist and combination therapy thereof for the treatment of cancer
CN113365659A (zh) 抗pd-l1抗体治疗头颈癌的用途
WO2020063433A1 (zh) 抗程序性死亡配体-1(pd-l1)抗体的抗肿瘤用途
KR20260054704A (ko) 항-pd-1 및 화학요법을 이용한 폐암 치료
JP2025519552A (ja) がんの治療のためのｓｉｒｐアルファ融合タンパク質及び抗ｃｄ１９抗体を含む併用療法
TW202523693A (zh) 手術前後基於抗ｐｄ－１之治療
TW202523359A (zh) 抗體-藥物結合物與抗pd-1/tim-3雙特異性結合蛋白質之組合

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230802

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250107

Comment text: Request for Examination of Application